Synlogic Inc

-0.0001 (-0.02%)


Draw Mode:

Volume 198,748
Bid Price 0.5702
Ask Price 0.6159
News -
Day High 0.6273


52 Week Range


Day Low 0.568
Company Name Stock Ticker Symbol Market Type
Synlogic Inc SYBX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0001 -0.02% 0.5924 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.58 0.568 0.6273 0.5924 0.5925
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
581 198,748 $ 0.5957494 $ 118,404 - 0.453 - 1.35
Last Trade Time Type Quantity Stock Price Currency
19:01:32 48 $ 0.5778 USD

Synlogic Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 40.41M 68.21M 43.06M $ 174.00k $ -156.22k -0.23 -258.67
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 248.08k 0.20%

more financials information »

Synlogic News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No SYBX Message Board. Create One! See More Posts on SYBX Message Board See More Message Board Posts

Historical SYBX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.550.660.4849610.5710236318,3570.04247.71%
1 Month0.5590.660.4849610.5627782198,0850.03345.97%
3 Months0.620.73480.4530.5393581342,325-0.0276-4.45%
6 Months0.661.100.4530.6335102228,569-0.0676-10.24%
1 Year1.171.350.4530.7647333186,668-0.5776-49.37%
3 Years2.405.110.4532.56389,449-1.81-75.32%
5 Years9.6114.590.4533.11325,418-9.02-93.84%

Synlogic Description

Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines which are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects.